

Cover Story
Guest Editorial
By John H. Stewart and Robert A. Winn
Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.
By Claire Dietz and Matthew Bin Han Ong
In Brief
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- NIH Director Jay Bhattacharya launches a podcast
- Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- As Trump decimates NIH funding, a daring proposal to issue $750 billion in bonds for medical cures garners attention
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- “Forward funding” NIH budget plan would make competing for grants much harder
- Optimizing dosing of expensive and toxic oncology drugs: Making America healthier